Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. cut its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,255 shares of the company’s stock after selling 2,750 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,068,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. New Covenant Trust Company N.A. purchased a new position in Teva Pharmaceutical Industries during the first quarter worth about $28,000. UMB Bank n.a. lifted its holdings in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after acquiring an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth $48,000. Byrne Asset Management LLC purchased a new position in Teva Pharmaceutical Industries during the second quarter worth about $52,000. Finally, Claro Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $52,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.57 on Thursday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The company has a market cap of $18.77 billion, a price-to-earnings ratio of -19.49, a price-to-earnings-growth ratio of 1.30 and a beta of 0.87. The stock’s 50-day moving average is $17.60 and its two-hundred day moving average is $17.35. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31.

Analyst Ratings Changes

A number of research analysts have commented on the company. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Barclays increased their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.